MarketLens
Sign Up

What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals

7 months ago
SHARE THIS ON:

What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

Capricor Therapeutics' PDUFA target action date for deramiocel was extended to November 22, 2026, after the FDA requested additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indi...
Stock News•1 months ago

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

NeuroPace's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
Stock News•2 months ago

Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition

Rhythm Pharmaceuticals' experimental weekly injectable reduced body weight in patients with a rare obesity form caused by brain damage, per preliminary mid-stage data released Tuesday.

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help